Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

Siemens Healthineers is debuting its first fully sealed 1.5 Tesla MRI scanner, designed to dramatically reduce its use of ...

After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance.

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...